Drug profile · INN
aflibercept
SKOJOY
- US status
- approved
- Patents linked
- 6
- News articles
- 0
Quick answer
aflibercept (SKOJOY) is an FDA-listed pharmaceutical active ingredient. Associated with Regeneron UK Limited. Route of administration: injection. Current US regulatory status: approved.
Key facts
Related patents
Search patents →-
US 11667702
Stable aqueous formulations of aflibercept
granted -
US 11535663
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
granted -
US 11472861
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
granted -
US 11426446
Stable aqueous formulations of aflibercept
granted -
US 11104715
Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
granted -
US 11071780
Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
granted
Frequently asked questions
What is aflibercept?
aflibercept (SKOJOY) is an FDA-listed pharmaceutical active ingredient. Associated with Regeneron UK Limited. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for aflibercept?
SKOJOY is a marketed brand name for aflibercept. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aflibercept?
aflibercept has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.